Goetzl Laura, Zighelboim Israel, Badell Martina, Rivers Jose, Mastrangèlo Mary Ann, Tweardy David, Suresh Maya S
Department of Obstetrics & Gynecology, Medical University of South Carolina, Charleston, SC, USA.
Am J Obstet Gynecol. 2006 Oct;195(4):1031-7. doi: 10.1016/j.ajog.2006.06.012. Epub 2006 Jul 26.
Intrauterine exposure to hyperthermia at term is associated with adverse neonatal neurologic outcomes. The objective of this study was to determine whether prophylactic maternal corticosteroid treatment prevents fetal exposure to hyperthermia and inflammatory cytokines after epidural analgesia.
A 2-phase, randomized, institutional review board-approved, double-blind, placebo-controlled trial was performed. Term nulliparous women were enrolled at epidural placement. Patients with a temperature of >99.4 degrees F or with diabetes mellitus were excluded. In phase 1, 25 mg methylprednisolone (low dose) or placebo was administered every 8 hours. In phase 2, the treatment dose was increased to 100 mg every 4 hours (high dose). Our primary outcome was a rate of intrapartum fever of >100.4 degrees F. Secondary outcomes were fetal interleukin-6 levels and the rate of neonatal bacteremia.
One hundred one patients were assigned randomly to placebo; 50 patients were assigned to the low-dose group, and 49 patients were assigned to the high-dose group. Treatment with the high dose resulted in a 90% reduction in maternal fever, compared with placebo and low dose therapy (2.0% vs 21.8% vs. 34.0%, respectively; P < .001). Neonatal sepsis evaluations were reduced significantly in the high-dose group (4.1% vs 17.8% vs 24%, respectively; P = .01), but the rates of asymptomatic bacteremia were increased (9.3% vs 0% vs 2.1%, respectively; P = .005). Median cord blood interleukin-6 levels were reduced with the high-dose steroid treatment, but this result was statistically significant only between the high-dose and placebo groups (24.0 +/- 38.5 vs 32.0 +/- 95.0 pg/mL, respectively; P = .02).
Prophylaxis with high-dose corticosteroids significantly reduces fetal exposure to hyperthermia and inflammation. However, maternal high-dose corticosteroids increase the rate of neonatal asymptomatic bacteremia. Stress-dose corticosteroid use in labor should trigger consideration of a screening neonatal blood culture.
足月时子宫内暴露于高温与不良新生儿神经学结局相关。本研究的目的是确定预防性母体皮质类固醇治疗是否能预防硬膜外镇痛后胎儿暴露于高温和炎性细胞因子。
进行了一项经机构审查委员会批准的两阶段随机双盲安慰剂对照试验。足月未产妇在硬膜外置管时入组。排除体温>99.4华氏度或患有糖尿病的患者。在第1阶段,每8小时给予25毫克甲泼尼龙(低剂量)或安慰剂。在第2阶段,治疗剂量增加至每4小时100毫克(高剂量)。我们的主要结局是产时发热>100.4华氏度的发生率。次要结局是胎儿白细胞介素-6水平和新生儿菌血症发生率。
101例患者被随机分配至安慰剂组;50例患者被分配至低剂量组,49例患者被分配至高剂量组。与安慰剂和低剂量治疗相比,高剂量治疗使母体发热降低了90%(分别为2.0%、21.8%和34.0%;P<.001)。高剂量组新生儿败血症评估显著减少(分别为4.1%、17.8%和24%;P=.01),但无症状菌血症发生率增加(分别为9.3%、0%和2.1%;P=.005)。高剂量类固醇治疗使脐血白细胞介素-6水平中位数降低,但该结果仅在高剂量组和安慰剂组之间具有统计学意义(分别为24.0±38.5和32.0±95.0 pg/mL;P=.02)。
高剂量皮质类固醇预防可显著减少胎儿暴露于高温和炎症。然而,母体高剂量皮质类固醇会增加新生儿无症状菌血症的发生率。产时使用应激剂量皮质类固醇应促使考虑进行新生儿血培养筛查。